Summit Partners Public Asset Management LLC Purchases 20,166 Shares of argenex SE $ARGX

Summit Partners Public Asset Management LLC increased its stake in shares of argenex SE (NASDAQ:ARGX) by 32.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 82,620 shares of the company’s stock after purchasing an additional 20,166 shares during the period. argenex accounts for 1.4% of Summit Partners Public Asset Management LLC’s investment portfolio, making the stock its 14th largest position. Summit Partners Public Asset Management LLC owned about 0.13% of argenex worth $69,479,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. American Century Companies Inc. increased its position in shares of argenex by 11.6% during the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock valued at $169,474,000 after purchasing an additional 23,864 shares during the last quarter. US Bancorp DE lifted its stake in shares of argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock valued at $5,217,000 after purchasing an additional 1,919 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of argenex in the 4th quarter valued at approximately $20,475,000. Sands Capital Management LLC purchased a new position in argenex during the third quarter valued at $12,262,000. Finally, Fiera Capital Corp increased its holdings in shares of argenex by 12.1% in the 3rd quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after purchasing an additional 19,180 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Down 0.6%

Shares of argenex stock opened at $878.49 on Wednesday. The stock’s 50-day simple moving average is $817.48 and its 200-day simple moving average is $810.99. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The company has a market capitalization of $54.63 billion, a price-to-earnings ratio of 39.11, a PEG ratio of 1.35 and a beta of 0.47.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%. On average, equities analysts expect that argenex SE will post 26.19 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on ARGX. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Glj Research raised argenex to a “strong-buy” rating in a report on Friday, April 3rd. Robert W. Baird lifted their price objective on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,019.50.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.